Article metrics
PDF
Other content recommended for you
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- Should rare diseases get special treatment?
- Rare childhood diseases: how should we respond?
- Estimating rare disease prevalence and costs in the USA: a cohort study approach using the Healthcare Cost Institute claims data
- Rare diseases in healthcare priority setting: should rarity matter?
- Agranulocytosis with deferiprone treatment of superficial siderosis
- Orphan drugs and the NHS: should we value rarity?
- Classical infratentorial superficial siderosis of the central nervous system: pathophysiology, clinical features and management
- Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis